Thanks to efforts by RWC-340B members and other covered entity advocates, 243 members of the House of Representatives (174 Democrat and 69 Republican members) signed a bipartisan letter (“Letter”) objecting…
Today, RWC-340B submitted to a letter to Secretary of the U.S. Department of Health and Human Services (HHS) Alex Azar requesting that HHS initiate enforcement actions, in the form of…
In a notice sent to covered entities and other 340B program participants, Eli Lilly and Co. (Lilly) announced that, effective September 1, 2020, it is implementing a limited distribution plan…
On August 26, Second Sight Solutions, the owner of the 340B ESP™ platform, hosted the second in a series of webinars on 340B ESP™. The webinar, entitled Data Security, Privacy,…
Here is a press statement from RWC-340B president Shannon Stephenson regarding the recent actions taken by drug manufacturers Lilly, Novartis, Merck, Sanofi, and Astra Zeneca. In the statement, RWC-340B calls…
This week, Kalderos announced that it is launching its new “340B Pay” platform which, if implemented, would fundamentally change how the 340B drug discount program operates – shifting a manufacturer’s…
On July 29, Reps. Doris Matsui (D-CA) and Chris Stewart (R-UT) introduced a bill that would protect 340B hospitals from losing their covered entity status and allow flexibility in how…
The Court of Appeals for District of Columbia Circuit issued a 2-1 decision today upholding Medicare Part B reimbursement cuts for 340B drugs from ASP+6% to ASP-22.5%. The case is…
On Friday, July 24, President Donald Trump signed four Executive Orders designed to lower the cost of prescription drugs. This alert will focus on three Orders that could impact 340B…
Following a recent announcement by drug manufacturer Merck, Sanofi recently sent letters to 340B covered entities with contract pharmacy arrangements to request that they participate in a new web-based platform, 340B…